We studied the reliability and validity of two versions (64 items and 32 items) of the Spanish translation of the Inventory of Interpersonal Problems (IIP-64 and IIP-32) and their usefulness as screening instruments for personality disorders in a sample of 190 outpatients and 66 healthy subjects. Patients were assessed using the IIP-64 and IIP-32, the Structured Clinical Interview for DSM-IV Axis II Personality Disorder diagnoses, and the Global Assessment of Functioning. The internal consistency and test-retest reliability were satisfactory. As theoretically predicted, factor analysis produced eight factors, and multidimensional scaling indicated the two dimensions of affiliation and dominance. Finally, a cutoff point of 87 for the IIP-64 showed 87% sensitivity and 85% specificity, whereas a cutoff point of 44 for the IIP-32 showed 82% sensitivity and 75% specificity. The Spanish versions of the IIP-32 and the IIP-64 are valid instruments for assessing interpersonal problems and for screening personality disorders in clinical practice.
Since the beginning of the COVID-19 pandemic, the use of telehealth was rapidly implemented without previous evidence. The ONCOTELEMD study aimed to evaluate the opinion of patients attended via telemedicine during this period and to study factors that condition patient preferences on its use. Included patients had a confirmed cancer diagnosis and were contacted by telephone between 13 March and 30 April 2020, in the Medical Oncology Service of Hospital Parc Taulí, Sabadell. A 12-question survey was presented to them between 4 February and 19 April 2021. Statistical analysis was carried out using chi-square and multivariable logistic regression tests. Six hundred forty-six patients were included; 487 responded to the survey. The median age was 68 years (27–90), 55.2% were female. Most patients had a surveillance visit (65.3%) and were diagnosed with colorectal or breast cancer (43% and 26.5%, respectively); 91.8% of patients were satisfied, and 60% would accept the use of telemedicine beyond the pandemic. Patients aged more than 50 years (OR 0.40; 95% CI, 0.19–0.81; p = 0.01) and diagnosed with breast cancer (OR 0.45; 95% CI, 0.26–0.69; p < 0.001) were less predisposed to adopt telehealth in the future. Patients agreed to be informed via telehealth of scan or lab results (62% and 84%, respectively) but not of new oral or endovenous treatments (52% and 33.5%, respectively). Additionally, 75% of patients had a medium or low-null technologic ability, and 51.3% would only use the telephone or video call to contact health professionals. However, differences were found according to age groups (p < 0.0001). In total, patients surveyed were satisfied with telemedicine and believed telehealth could have a role following the COVID-19 pandemic. Moreover, our results remark on the importance of individualizing the use of telehealth, showing relevant data on patient preferences and digital literacy.
The category of non-clear cell renal cell carcinoma (nccRCC) includes several clinically, histologically, and molecularly diverse entities. Traditionally, they comprise type 1 and type 2 papillary, chromophobe, unclassified, and other histologies (medullary, collecting duct carcinoma, and translocation-associated). Molecular knowledge has allowed the identification of some other specific subtypes, such as fumarate hydratase–deficient renal cell carcinoma (RCC) or succinate dehydrogenase–associated RCC. In addition, it has recognized some alterations with a possible predictive role, e.g., MET proto-oncogene receptor tyrosine kinase (MET) alterations in papillary tumors. Standard therapies for the management of advanced clear cell RCC (ccRCC), i.e., vascular endothelial growth factor receptor (VEGFR) pathway inhibitors and mammalian target of rapamycin inhibitors, have shown poorer results in nccRCC patients. Therefore, there is a need to improve the efficacy of the treatment for advanced nccRCC. Immunotherapy, especially immune checkpoint inhibitors (ICIs) targeting programmed death 1/programmed death ligand 1 and cytotoxic T-lymphocyte associated protein 4 (CTLA-4), has demonstrated a significant survival benefit in several malignant neoplasias, including ccRCC, with a proportion of patients achieving long survival. The combinations of ICI or ICI + VEGFR tyrosine kinase inhibitors (TKIs) are the standard of care in advanced ccRCC. Unfortunately, major pivotal trials did not include specific nccRCC populations. In recent years, several studies have retrospectively or prospectively evaluated ICIs alone or in combination with another ICI or with TKIs in nccRCC patients. In this article, we review data from available trials in order to elucidate clinical and molecular profiles that could benefit from immunotherapy approaches.
BACKGROUND Since the beginning of the COVID-19 pandemic, the use of telehealth for cancer care was rapidly implemented without previous experience. Afterwards, few published studies have assessed patient’s perception with the use of telemedicine during this period. The main objective of ONCOTELEMD study was to evaluate the opinion of patients attended via telemedicine during the first quarter of 2020 in the Medical Oncology Service of Hospital Parc Taulí, Sabadell. METHODS 646 patients were visited via telephone between March 13 and April 30 2020. A 12-question survey was presented to them between February 4 and April 19 2021. Statistical analysis was carried out using Chi-square test. RESULTS 487 patients responded. Median age was 68 years [27–90]. 90% of patients were satisfied with the telephone visit and 60% would agree to switch some in-person to virtual visits in the future. In general, patients agreed to be informed via telehealth of radiological/analytical results but not of new oral or endovenous treatments. 75% of patients had a medium or low-null knowledge of new technologies. However, statistical significant differences were found according to age groups. 60% of patients younger than 50 years would prefer to have different technological tools to contact their oncologist whereas 58% of patients older than 70 years would prefer only telephone or video-calls. CONCLUSIONS In global, patients surveyed were satisfied with the virtual visit and believe that telehealth could have a role following COVID-19 pandemic. Nevertheless, it is necessary to individualize its use according to patient’s preferences and conditions.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.